NCT03207529 - Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Androgen Receptor PositiveHER2/Neu NegativeMetastatic Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8PTEN PositiveRecurrent Breast CarcinomaRefractory Breast CarcinomaTriple-Negative Breast Carcinoma

Interventions

DRUG

Alpelisib

Given PO

DRUG

Enzalutamide

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER